Mig (Ibuprofen)

Ibuprofen works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. Lower prostaglandin levels result in decreased inflammation, pain signaling, and fever response.

The appropriate dose of Mig is determined by a qualified prescriber based on the individual’s age, weight, medical condition, and response to therapy. Patients should follow the healthcare professional’s instructions and the product labeling.

Ibuprofen is generally avoided in the third trimester of pregnancy because of potential risks to the fetus. During the first and second trimesters, use only if clearly needed and prescribed. Ibuprofen passes into breast milk in small amounts; nursing mothers should consult a healthcare provider before use.

To order Mig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ibuprofen (Mig) and naproxen belong to the NSAID class and share similar mechanisms of COX inhibition. Ibuprofen generally has a shorter half‑life, requiring more frequent dosing, while naproxen offers longer duration of action. Choice between them depends on individual patient response, dosing convenience, and specific safety considerations.

Mig should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Mig is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food or milk may reduce the likelihood of stomach upset.

Serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, kidney injury, liver dysfunction, and cardiovascular events like heart attack or stroke. Patients should seek immediate medical attention if they notice symptoms such as black stools, severe abdominal pain, swelling, or breathing difficulties.

Mig should be avoided by individuals with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients with severe renal or hepatic impairment, and pregnant women in the third trimester. Consultation with a healthcare professional is essential before starting therapy.